PODCAST | Politics, Policy & Law
Treating Trump & BMS’s $13B MyoKardia buy: a BioCentury podcast
Editors also discuss key takeaways from drug pricing hearings, preview 4Q20
October 6, 2020 3:12 AM UTC
In the latest BioCentury This Week podcast, BioCentury’s editors discuss access to Regeneron’s experimental COVID-19 therapy, fallout from last week’s House drug pricing hearings, Bristol Myers’ heart pumping $13 billion takeout of MyoKardia and the outlook for the biotech fund-raising environment in 4Q20.
Washington Editor Steve Usdin and Editor in Chief Simone Fishburn dig into how the president’s treatment with an investigational drug from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)
resurfaces long-standing ethical quandaries involving compassionate use and the allocation of scarce drugs. ...